ClinicalTrials.gg
CompletedNCT03927690Updated Jun 20, 2024Results posted

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

A Phase 2 interventional study of LKA651 and Lucentis in Diabetic Macular Edema, sponsored by Novartis Pharmaceuticals. Completed at 22 sites in 5 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-06-20.

Primary conditionMacular EdemaRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Macular Edema
Why
  1. The study's listed conditions name Macular Edema, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
38th of 91
91 · median 50
Started
2019
the only one that year
Phase 2
19 of 91
none open now
Registered
83rd of 91
by date
Lead sponsor
21 of 91
Novartis Pharmaceuticals

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 38th largest by enrollment, is the only one that started in 2019, is one of 19 in phase 2, and was the 83rd registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),

Read the detailed description

This study was a 3-arm, parallel group, randomized, patient- and investigator-masked trial planned in 90 patients with Diabetic macular edema (DME). The study consisted of a screening period of 60 days, main study (12 weeks), and an extension period (12 weeks). The study was stratified such that sentinel safety cohorts were first enrolled to test the safety of the combination of LKA651 and Lucentis before proceeding with further patient randomization. After determination of safety from Day 15 data from each sentinel cohort, patients were enrolled into 1 of 3 arms: LKA651 monotherapy, LKA651 plus Lucentis, and Lucentis monotherapy. Every patient was dosed 3 times in 4 week intervals in the treatment phase and was then followed up for an extension phase of an additional 12 weeks during which Lucentis was allowed to be administered as rescue at the discretion of the Investigator. No predefined rescue criteria were outlined as guidance.

03

Conditions studied

  • Diabetic Macular Edema

Keywords

  • Macular degeneration
  • age-related macular degeneration (ARMD)
  • vision loss
  • macula damage
  • retina damage
  • dry macular degeneration
  • wet macular degeneration
  • AMD
  • diabetic macular edema
  • DME
  • neovascular age-related macular degeneration
  • nAMD
  • retinal vein occlusion
  • RVO
  • Diabetic Macular edema (DME)
  • macular edema
  • diabetic retinopathy
  • LKA651
  • Lucentis
04

In context

Macular Edema Reclassified

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

This study's enrollment of 91 is above the median of 56 across 586 interventional studies indexed under Macular Edema.

Browse Macular Edema studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed.
  • Male and female patients age 18 to 85 years of age inclusive at screening
  • Presence of type I or type II diabetes mellitus
  • The Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye must be between 24 and 70 letters (approximate Snellen equivalent of 20/40-20/320). The non-study eye (fellow eye) should be ≥34 letters or better (approximate Snellen equivalent of 20/200) at screening
  • Presence of Diabetic macular edema (DME) in the study eye, with decrease in vision due to foveal thickening of central macular thickness ≥ 320 µm in the central subfield, as assessed on Spectral domain optical coherence tomography (SD-OCT) and confirmed by the central reading center at screening
  • Sufficiently clear ocular media and adequate pupil dilation in the study eye to permit fundus photographs of adequate clarity to measure diameters of retinal arteries and veins at screening

Exclusion criteria

Exclusion criteria

  • Patient with history of intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) treatment in the study eye \<90 days from baseline
  • Patient with history of intraocular including dexamethasone intravitreal implants during the 6 month period prior to baseline. Any prior use of fluocinolone acetonide intravitreal implant (Iluvien) is prohibited regardless of timing
  • Laser photocoagulation (macular or panretinal) in the study eye during the 3-month period prior to baseline.
  • High risk proliferative diabetic retinopathy
  • Patients, with type 1 or type 2 diabetes who have a ≥ 12% at screening.
  • Any progressive disease of the retina in the study eye (e.g. uveitis,rod-cone dystrophy) or optic nerve
  • Area of macular retinal ischemia (as measured by the foveal avascular zone) ≥ 1000 μm.
  • Active intraocular inflammation (graded as trace or above) or active intraocular infection in either eye.
  • Current diagnosis of or laboratory evidence for anemia, defined as a \<10 g/dL for women and \<11 g/dL for men.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    LKA651

    LKA651 Intravitreal injection

    Drug: LKA651

  • Experimental
    LKA651 + Lucentis

    LKA651 + Lucentis Intravitreal injection

    Drug: LKA651 · Drug: Lucentis

  • Active comparator
    Lucentis

    Lucentis Intravitreal injection

    Drug: Lucentis

Interventions

  • DrugLKA651

    LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase

  • Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase

07

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient. The severity of the AEs (mild, moderate, severe) was based on the Common Terminology Criteria for Adverse Events (CTCAE). Number of participants in each category is reported in the table. A participant who falls multiple times in one category is counted only once.

    Time frame: Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).

  2. Number of Participants With Ocular Adverse Events by Preferred Term in Study Eye

    An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient.

    Time frame: Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).

  3. Number of Participants With Non-ocular Adverse Events (>=2%)

    An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient.

    Time frame: Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).

  4. Intraocular Pressure (IOP) in Study Eye

    Intraocular pressure was measured per the study site's regular practice.

    Time frame: Screening, and Day 85

  5. Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Charts in Study Eye

    BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Visual function of the study eye was assessed using the ETDRS protocol. BCVA in study eye was analyzed with a mixed model for repeated measures. The model included treatment, visit, and the treatment by visit interaction as independent variables. An unstructured residual covariance structure was used. Baseline BCVA value and treatment naïve and treatment experienced variable were used as covariates. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.

    Time frame: Days 2, 8, 15, 29, 43, 57, and 85

  6. Inner Macular Thickness (Inferior)

    Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).

    Time frame: Week 12 (Day 85)

  7. Inner Macular Thickness (Temporal)

    Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).

    Time frame: Week 12 (Day 85)

  8. Outer Macular Thickness (Inferior)

    Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).

    Time frame: Week 12 (Day 85)

  9. Outer Macular Thickness (Temporal)

    Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).

    Time frame: Week 12 (Day 85)

  10. Number of Participants Without Changes in Foveal Avascular Zone as Measured by Fluorescein Angiography (FA) in Study Eye

    Foveal avascular zone was assessed by fluorescein angiography (FA).

    Time frame: Days 29, 57, 85, End of Study (Up to Day 140)

  11. Mixed Model Repeated Measures Analysis of Ratio to Baseline in Central Subfield Retinal Thickness (CSFT) in the Study Eye

    Central subfield thickness was measured by spectral domain optical coherence tomography (SD-OCT). Central subfield retinal thickness was analyzed with a mixed model for repeated measures. The model included treatment, visit, and the treatment by visit interaction as independent variables. An unstructured residual covariance structure was used. Log-transformed baseline central subfield retinal thickness and treatment naïve and treatment experienced variable were used as covariates. Results were back-transformed to show results as a ratio to baseline.

    Time frame: Days 8, 15, 29, 43, 57, 85

Secondary outcomes

  1. Number of Participants Who Needed Retreatment With Anti-VEGF in Study Eye After Week 12

    Time frame: Week 12 (Day 85) up to Day 140

  2. Time to Retreatment in Study Eye With Anti-VEGF After Week 12

    Time to retreatment with anti VEGF (as determined by the investigator) after Week 12 during the additional 12 week extension phase (that was up to 16 weeks after the last dose) was examined with a Kaplan Meier plot.

    Time frame: Week 12 (Day 85) up to Day 140

  3. Summary Statistics of Pharmacokinetics - Serum Concentrations of LKA651

    PK parameters were determined using non-compartmental methods using the most recent version of WinNonlin Phoenix (Version 8.2). Concentrations below the lower limit of quantification (LLOQ) were treated as 1/2 LLOQ in summary statistics.

    Time frame: Day 1 (0, 0.5 and 4 hrs post dose), Day 2, Day 8, Day 15, Day 29 (0, 0.5 and 4 hrs post dose), Day 43, Day 57 (0, 0.5 and 4 hrs post dose), Day 85

  4. Summary Statistics of Pharmacokinetics - AUC0-28d of LKA651 (Serum)

    Area under the curve over the dosing interval 0 to 28 days.

    Time frame: Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85

  5. Summary Statistics of Pharmacokinetics - Serum Concentrations of Lucentis

    Time frame: Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85

  6. Summary Statistics of Pharmacokinetics - AUC0-28d of Lucentis (Serum)

    Area under the curve over the dosing interval 0 to 28 days.

    Time frame: Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85

08

Results

Posted Oct 12, 2023

Participant flow

Participant flow — Overall Study
MilestoneLKA651LKA651 + LucentisLucentis
Started283033
Completed212731
Not completed732
Withdrew: Withdrawal by subject311
Withdrew: Adverse event100
Withdrew: Death100
Withdrew: Lost to follow-up221

Outcome measures

PrimaryNumber of Participants With Adverse Events

An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient. The severity of the AEs (mild, moderate, severe) was based on the Common Terminology Criteria for Adverse Events (CTCAE). Number of participants in each category is reported in the table. A participant who falls multiple times in one category is counted only once.

Time frame:
Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsLKA651LKA651 + LucentisLucentis
AEs, Patients with AEs201619
AEs of mild intensity161519
AEs of moderate intensity863
AEs of severe intensity421
Study drug-related AEs212
Serious AEs341
AEs leading to discontinuation of study treatment100
Study-drug related AEs leading to discontinuation of study treatment100
Non-serious AEs201619
PrimaryNumber of Participants With Ocular Adverse Events by Preferred Term in Study Eye

An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient.

Time frame:
Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).
Reported as:
Count of participants · Participants
Number of Participants With Ocular Adverse Events by Preferred Term in Study Eye
ParticipantsLKA651LKA651 + LucentisLucentis
Patients with at least one ocular AE in study eye1179
Conjunctival haemorrhage142
Diabetic retinal oedema212
Diabetic retinopathy111
Visual acuity reduced300
Vitreous haemorrhage102
Dry eye011
Macular oedema200
Ocular hypertension200
Abnormal sensation in eye001
Anterior chamber flare010
Corneal erosion100
Cystoid macular oedema100
Dacryostenosis acquired100
Eye pain100
Eyelids pruritus001
Lenticular opacities001
Punctate keratitis010
Retinal cyst100
Retinal detachment100
Retinal exudates100
Retinal haemorrhage100
Vitreoretinal traction syndrome001
PrimaryNumber of Participants With Non-ocular Adverse Events (>=2%)

An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient.

Time frame:
Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).
Reported as:
Count of participants · Participants
Number of Participants With Non-ocular Adverse Events (>=2%)
ParticipantsLKA651LKA651 + LucentisLucentis
Number of Participants With Non-ocular Adverse Events (>=2%)161514
PrimaryIntraocular Pressure (IOP) in Study Eye

Intraocular pressure was measured per the study site's regular practice.

Time frame:
Screening, and Day 85
Reported as:
Mean · mmHg
Intraocular Pressure (IOP) in Study Eye
mmHgLKA651LKA651 + LucentisLucentis
Screening15.1 ± 3.2014.9 ± 3.4415.5 ± 2.88
Day 8515.5 ± 3.5615.6 ± 3.6715.2 ± 3.79
PrimaryBest Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Charts in Study Eye

BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. Visual function of the study eye was assessed using the ETDRS protocol. BCVA in study eye was analyzed with a mixed model for repeated measures. The model included treatment, visit, and the treatment by visit interaction as independent variables. An unstructured residual covariance structure was used. Baseline BCVA value and treatment naïve and treatment experienced variable were used as covariates. Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.

Time frame:
Days 2, 8, 15, 29, 43, 57, and 85
Reported as:
Mean · Scores on a scale
Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Charts in Study Eye
Scores on a scaleLKA651LKA651 + LucentisLucentis
Day 261.5 (58.6 to 64.4)64.4 (62.3 to 66.6)64.1 (61.8 to 66.5)
Day 865.2 (61.7 to 68.7)68.6 (66.1 to 71.2)66.2 (63.4 to 69.0)
Day 1565.9 (62.4 to 69.4)68.6 (65.8 to 71.4)68.4 (65.4 to 71.3)
Day 2965.5 (62.6 to 68.4)68.2 (65.3 to 71.0)68.5 (65.9 to 71.1)
Day 4367.8 (64.4 to 71.1)70.4 (67.6 to 73.3)69.1 (66.2 to 71.9)
Day 5767.6 (64.7 to 70.5)71.5 (68.6 to 74.4)70.0 (67.4 to 72.6)
Day 8567.8 (64.8 to 70.9)72.5 (69.5 to 75.4)70.5 (67.8 to 73.2)
Statistical analysis
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 0.887 · Difference (test vs reference): -2.6 · 90% CI -6.2 to 1.0Comparison of model-based mean estimates.
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.431 · Difference (test vs reference): 0.3 · 90% CI -2.6 to 3.2Comparison of model-based mean estimates.
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 0.647 · Difference (test vs reference): -1.0 · 90% CI -5.4 to 3.4Comparison of model-based mean estimates.
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.130 · Difference (test vs reference): 2.4 · 90% CI -1.1 to 6.0Comparison of model-based mean estimates.
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 0.818 · Difference (test vs reference): -2.5 · 90% CI -6.9 to 2.0Comparison of model-based mean estimates
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.457 · Difference (test vs reference): 0.3 · 90% CI -3.6 to 4.1Comparison of model-based mean estimates.
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 0.906 · Difference (test vs reference): -3.1 · 90% CI -6.9 to 0.8Comparison of model-based mean estimates.
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.566 · Difference (test vs reference): -0.4 · 90% CI -4.1 to 3.3Comparison of model-based mean estimates.
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 0.686 · Difference (test vs reference): -1.3 · 90% CI -5.6 to 3.1Comparison of model-based mean estimates.
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.280 · Difference (test vs reference): 1.4 · 90% CI -2.5 to 5.2Comparison of model-based mean estimates.
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 0.849 · Difference (test vs reference): -2.4 · 90% CI -6.3 to 1.4Comparison of model-based mean estimates.
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.254 · Difference (test vs reference): 1.5 · 90% CI -2.2 to 5.2Comparison of model-based mean estimates.
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 0.866 · Difference (test vs reference): -2.7 · 90% CI -6.6 to 1.3Comparison of model-based mean estimates.
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.198 · Difference (test vs reference): 2.0 · 90% CI -1.9 to 5.8Comparison of model-based mean estimates.
PrimaryInner Macular Thickness (Inferior)

Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).

Time frame:
Week 12 (Day 85)
Reported as:
Mean · micrometer
Inner Macular Thickness (Inferior)
micrometerLKA651LKA651 + LucentisLucentis
Inner Macular Thickness (Inferior)503.06 ± 137.235400.82 ± 53.180390.48 ± 48.097
PrimaryInner Macular Thickness (Temporal)

Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).

Time frame:
Week 12 (Day 85)
Reported as:
Mean · micrometer
Inner Macular Thickness (Temporal)
micrometerLKA651LKA651 + LucentisLucentis
Inner Macular Thickness (Temporal)505.27 ± 141.410414.64 ± 67.032404.93 ± 56.099
PrimaryOuter Macular Thickness (Inferior)

Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).

Time frame:
Week 12 (Day 85)
Reported as:
Mean · micrometer
Outer Macular Thickness (Inferior)
micrometerLKA651LKA651 + LucentisLucentis
Outer Macular Thickness (Inferior)388.66 ± 88.128349.39 ± 44.538342.88 ± 50.612
PrimaryOuter Macular Thickness (Temporal)

Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT).

Time frame:
Week 12 (Day 85)
Reported as:
Mean · micrometer
Outer Macular Thickness (Temporal)
micrometerLKA651LKA651 + LucentisLucentis
Outer Macular Thickness (Temporal)404.60 ± 103.616371.83 ± 70.124352.24 ± 56.793
PrimaryNumber of Participants Without Changes in Foveal Avascular Zone as Measured by Fluorescein Angiography (FA) in Study Eye

Foveal avascular zone was assessed by fluorescein angiography (FA).

Time frame:
Days 29, 57, 85, End of Study (Up to Day 140)
Reported as:
Count of participants · Participants
Number of Participants Without Changes in Foveal Avascular Zone as Measured by Fluorescein Angiography (FA) in Study Eye
ParticipantsLKA651LKA651 + LucentisLucentis
Day 29 - NO CHANGE31611
Day 57 - NO CHANGE3167
Day 85 - NO CHANGE212529
End of Study (Up to Day 140) - NO CHANGE172230
End of Study (Up to Day 140) - CANNOT GRADE—1—
PrimaryMixed Model Repeated Measures Analysis of Ratio to Baseline in Central Subfield Retinal Thickness (CSFT) in the Study Eye

Central subfield thickness was measured by spectral domain optical coherence tomography (SD-OCT). Central subfield retinal thickness was analyzed with a mixed model for repeated measures. The model included treatment, visit, and the treatment by visit interaction as independent variables. An unstructured residual covariance structure was used. Log-transformed baseline central subfield retinal thickness and treatment naïve and treatment experienced variable were used as covariates. Results were back-transformed to show results as a ratio to baseline.

Time frame:
Days 8, 15, 29, 43, 57, 85
Reported as:
Geometric mean · ratio
Mixed Model Repeated Measures Analysis of Ratio to Baseline in Central Subfield Retinal Thickness (CSFT) in the Study Eye
ratioLKA651LKA651 + LucentisLucentis
Day 80.99 (0.92 to 1.07)0.83 (0.78 to 0.88)0.83 (0.78 to 0.88)
Day 150.97 (0.90 to 1.05)0.83 (0.78 to 0.88)0.80 (0.76 to 0.86)
Day 291.00 (0.94 to 1.05)0.80 (0.76 to 0.85)0.82 (0.78 to 0.86)
Day 431.04 (0.97 to 1.13)0.76 (0.71 to 0.81)0.79 (0.74 to 0.84)
Day 570.95 (0.89 to 1.00)0.75 (0.70 to 0.80)0.80 (0.76 to 0.84)
Day 850.97 (0.91 to 1.05)0.75 (0.70 to 0.80)0.78 (0.73 to 0.83)
Statistical analysis
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 0.998 · Ratio (test vs reference): 1.20 · 90% CI 1.08 to 1.33Comparison of model-based mean estimates.
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.527 · Ratio (test vs reference): 1.00 · 90% CI 0.92 to 1.09Comparison of model-based mean estimates.
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 0.999 · Ratio (test vs reference): 1.21 · 90% CI 1.10 to 1.33Comparison of model-based mean estimates
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.716 · Ratio (test vs reference): 1.03 · 90% CI 0.95 to 1.12Comparison of model-based mean estimates.
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 1.000 · Ratio (test vs reference): 1.21 · 90% CI 1.13 to 1.31Comparison of model-based mean estimates.
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.281 · Ratio (test vs reference): 0.98 · 90% CI 0.91 to 1.05Comparison of model-based mean estimates.
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 1.000 · Ratio (test vs reference): 1.32 · 90% CI 1.20 to 1.46Comparison of model-based mean estimates.
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.200 · Ratio (test vs reference): 0.96 · 90% CI 0.88 to 1.04Comparison of model-based mean estimates.
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 1.000 · Ratio (test vs reference): 1.18 · 90% CI 1.09 to 1.28Comparison of model-based mean estimates.
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.083 · Ratio (test vs reference): 0.94 · 90% CI 0.87 to 1.01Comparison of model-based mean estimates.
  • LKA651 vs Lucentis · Mixed model repeated measures analysis · p = 1.000 · Ratio(test vs reference): 1.26 · 90% CI 1.14 to 1.38Comparison of model-based mean estimates.
  • LKA651 + Lucentis vs Lucentis · Mixed model repeated measures analysis · p = 0.254 · Ratio(test vs reference): 0.96 · 90% CI 0.88 to 1.06Comparison of model-based mean estimates.
SecondaryNumber of Participants Who Needed Retreatment With Anti-VEGF in Study Eye After Week 12
Time frame:
Week 12 (Day 85) up to Day 140
Reported as:
Count of participants · Participants
Number of Participants Who Needed Retreatment With Anti-VEGF in Study Eye After Week 12
ParticipantsLKA651LKA651 + LucentisLucentis
Number of Participants Who Needed Retreatment With Anti-VEGF in Study Eye After Week 12161621
SecondaryTime to Retreatment in Study Eye With Anti-VEGF After Week 12

Time to retreatment with anti VEGF (as determined by the investigator) after Week 12 during the additional 12 week extension phase (that was up to 16 weeks after the last dose) was examined with a Kaplan Meier plot.

Time frame:
Week 12 (Day 85) up to Day 140
Reported as:
Median · Days after Day 85 (Week 12)
Time to Retreatment in Study Eye With Anti-VEGF After Week 12
Days after Day 85 (Week 12)LKA651LKA651 + LucentisLucentis
Time to Retreatment in Study Eye With Anti-VEGF After Week 1255.0 (17.0 to NA)34.0 (12.0 to NA)31.0 (9.0 to 109.0)
SecondarySummary Statistics of Pharmacokinetics - Serum Concentrations of LKA651

PK parameters were determined using non-compartmental methods using the most recent version of WinNonlin Phoenix (Version 8.2). Concentrations below the lower limit of quantification (LLOQ) were treated as 1/2 LLOQ in summary statistics.

Time frame:
Day 1 (0, 0.5 and 4 hrs post dose), Day 2, Day 8, Day 15, Day 29 (0, 0.5 and 4 hrs post dose), Day 43, Day 57 (0, 0.5 and 4 hrs post dose), Day 85
Reported as:
Mean · ng/mL
Summary Statistics of Pharmacokinetics - Serum Concentrations of LKA651
ng/mLLKA651LKA651 + LucentisLucentis
Day 1 - 0 hrs0.00 ± 0.000.00 ± 0.00—
Day 1 - 0.5 hrs post dose0.000.00 ± 0.00—
Day 1 - 4 hrs post dose114 ± 2114.43 ± 17.1—
Day 236.3 ± 29.28.13 ± 21.6—
Day 816.2 ± 27.52.08 ± 8.06—
Day 157.24 ± 16.20.00 ± 0.00—
Day 29 - 0 hrs0.00 ± 0.000.00 ± 0.00—
Day 29 - 0.5 hrs post dose0.000.00 ± 0.00—
Day 29 - 4 hrs post dose—7.60 ± 18.6—
Day 430.000.00 ± 0.00—
Day 57 - 0 hrs0.00 ± 0.000.00 ± 0.00—
Day 57 - 0.5 hrs post dos0.000.00 ± 0.00—
Day 57 - 4 hrs post dose—0.00 ± 0.00—
Day 850.00 ± 0.000.00 ± 0.00—
SecondarySummary Statistics of Pharmacokinetics - AUC0-28d of LKA651 (Serum)

Area under the curve over the dosing interval 0 to 28 days.

Time frame:
Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85

No measurements were reported for this outcome.

SecondarySummary Statistics of Pharmacokinetics - Serum Concentrations of Lucentis
Time frame:
Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85

No measurements were reported for this outcome.

SecondarySummary Statistics of Pharmacokinetics - AUC0-28d of Lucentis (Serum)

Area under the curve over the dosing interval 0 to 28 days.

Time frame:
Day 1 - 4 hrs post dose, Day 2, Day 8, Day 15, Day 29 - 4 hrs post dose, Day 43, Day 57 - 4 hrs post dose, Day 85

No measurements were reported for this outcome.

Post-hocAll Collected Deaths

On-treatment deaths are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days). Post-treatment deaths are reported for the timeframe of greater than 30 days after last treatment, until study completion, up to approximately 168 days. All deaths refer to the sum of on-treatment and post-treatment deaths.

Time frame:
On-treatment - up to 12 weeks; Post-treatment - greater than 30 days after last treatment, until study completion, up to approximately 168 days
Reported as:
Count of participants · Participants
All Collected Deaths
ParticipantsLKA651LKA651 + LucentisLucentis
On-Treatment Deaths000
Post-Treatment Deaths100
All Deaths100

Adverse events

Collected over Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LKA6511/28 (3.6%)3/28 (10.7%)20/28 (71.4%)
LKA651 + Lucentis0/30 (0%)4/30 (13.3%)16/30 (53.3%)
Lucentis0/33 (0%)1/33 (3%)19/33 (57.6%)
Total1/91 (1.1%)8/91 (8.8%)55/91 (60.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventLKA651LKA651 + LucentisLucentisTotal
Retinal detachmentEye disorders1/280/300/331/91
COVID-19 pneumoniaInfections and infestations1/280/300/331/91
Haemorrhagic strokeNervous system disorders1/280/300/331/91
Angina unstableCardiac disorders0/281/300/331/91
Cyclic vomiting syndromeGastrointestinal disorders0/281/300/331/91
Varices oesophagealGastrointestinal disorders0/281/300/331/91
DehydrationMetabolism and nutrition disorders0/281/300/331/91
Bone cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/281/300/331/91
Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/281/300/331/91
Confusional statePsychiatric disorders0/281/300/331/91
Most frequent other events
Showing 10 of 89
Most frequent other events
EventLKA651LKA651 + LucentisLucentisTotal
Conjunctival haemorrhageEye disorders1/285/302/338/91
Diabetic retinal oedemaEye disorders3/281/302/336/91
Visual acuity reducedEye disorders3/280/300/333/91
HypertensionVascular disorders3/281/303/337/91
Macular oedemaEye disorders2/280/300/332/91
Ocular hypertensionEye disorders2/280/300/332/91
COVID-19Infections and infestations2/280/300/332/91
Blood creatinine increasedInvestigations2/280/300/332/91
HyperglycaemiaMetabolism and nutrition disorders2/281/301/334/91
AnaemiaBlood and lymphatic system disorders1/282/301/334/91

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LKA651LKA651 + LucentisLucentisTotal
Mean61.6 ± 8.5863.8 ± 8.1861.2 ± 9.0262.2 ± 8.60
Sex: Female, Male
Sex: Female, Male(Participants)LKA651LKA651 + LucentisLucentisTotal
Female9131032
Male19172359
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LKA651LKA651 + LucentisLucentisTotal
American Indian or Alaska Native0112
Asian2103
Native Hawaiian or Other Pacific Islander0101
Black or African American3003
White23273282
More than one race0000
Unknown or Not Reported0000
09

Study locations

22 sites
  • Novartis Investigative Site
    Beverly Hills, California 90211, United States
  • Novartis Investigative Site
    Rancho Cordova, California 95670, United States
  • Novartis Investigative Site
    Miami, Florida 33143, United States
  • Novartis Investigative Site
    'Aiea, Hawaii 96701, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02118, United States
  • Novartis Investigative Site
    Austin, Texas 78750, United States
  • Novartis Investigative Site
    San Antonio, Texas 78240, United States
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Gottingen, 37075, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Muenster, 48145, Germany
  • Novartis Investigative Site
    Tuebingen, 72076, Germany
  • Novartis Investigative Site
    Arecibo, 00612, Puerto Rico
  • Novartis Investigative Site
    Sevilla, Andalucia 41009, Spain
  • Novartis Investigative Site
    Sant Cugat, Catalunya 08190, Spain
  • Novartis Investigative Site
    Barcelona, 08025, Spain
  • Novartis Investigative Site
    Cordoba, 14012, Spain
  • Novartis Investigative Site
    Zaragoza, 50009, Spain
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Ankara, 06490, Turkey
  • Novartis Investigative Site
    Ankara, 06500, Turkey
  • Novartis Investigative Site
    Kocaeli, 41380, Turkey
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jun 2022, 36 months.

Results were first posted in Oct 2023, 1 year 3 months after primary completion. A results delay was requested in May 2023.

Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 36 months is above that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2019
First posted
Apr 25, 2019
StartActual
May 24, 2019
Primary completionActual
Jun 17, 2022
CompletionActual
Aug 31, 2022
Results delay requested
May 1, 2023
Results first posted
Oct 12, 2023
Last update
Jun 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03927690
Responsible party
Sponsor
First posted
Apr 25, 2019
Start date
May 24, 2019
Primary completion
Jun 17, 2022
Completion
Aug 31, 2022
Results posted
Oct 12, 2023
Last update
Jun 20, 2024

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: LKA651 · Ranibizumab

Start the discussion